The antimicrobial susceptibility of 176 unusual non-fermentative gram-negative bacilli (NF-GNB) 
Susceptibility testing -Antimicrobial susceptibility testing was performed using the reference broth mi-crodilution method as described by the National Committee for Clinical Laboratory Standards (NCCLS 2003) . The susceptibility and resistance rates were calculated according to the NCCLS breakpoints (M100-S14) established for testing non-Enterobacteriaceae isolates (NCCLS 2004) . Antimicrobial agents were obtained from the respective manufacturers. Quality control was performed by testing Pseudomonas aeruginosa ATCC 27853, Escherichia coli ATCC 25922, Staphylococcus aureus ATCC 29213, and Enterococcus faecalis ATCC 29212.
REsULTs AND DIsCUssION
NF-GNB other than P. aeruginosa, Acinetobacter spp., and Stenotrophomonas maltophilia are uncommon pathogens; however, they represent a real challenge for the routine clinical microbiology laboratories since species identification is complex and antimicrobial susceptibility profile is unpredictable. Table I shows the frequency of occurrence of NF-GNB isolated from Latin American medical centers during the first six years of SENTRY program (1997) (1998) (1999) (2000) (2001) (2002) . B. cepacia (45.5%) was the most frequently isolated NF-GNB, independent of the year of isolation, followed by Achromobacter xylosoxidans (12.5%) and Ralstonia pickettii (9.1%). Overall the Brazilian medical centers contributed with the largest number of strains (91 isolates; 51.7%) followed by the Argentinean (32 isolates; 18.1%) and Colombian (20 isolates, 11.4%) medical centers. A single Brazilian medical center (number 048) provided 25% of the NF-GNB strains.
The distribution of the NF-GNB according to the site of infection is demonstrated in Table II . The majority (67%) of NF-GNB strains were isolated from bloodstream infections. All pathogens were more frequently isolated from bloodstream infections with the exception of Cryseobacterium spp. and Alcaligenes spp. isolates. Cryseobacterium spp. strains were equally isolated from blood and respiratory tract infections, while Alcaligenes spp. strains were more frequently isolated from skin and soft tissue infections.
Antimicrobial susceptibility data on unusual NF-GNB is very scarce (Gales et al. 2001 , Jones et al. 2003 , Sader & Jones 2005 . Changes in the nomenclature, use of disk-diffusion technique, and the isolation of low number of isolates make difficult to consider most of the published data. The most recent NCCLS documents do not include recommendations for the optimal antimicrobial susceptibility testing method for these NF-GNB, nor the antimicrobial agents that should be tested (NCCLS 2003 (NCCLS , 2004 . We tested a panel of antimicrobial agents with activity against gram-negative bacilli by broth microdilution and used susceptibility breakpoints established for nonEnterobacteriaceae to evaluate the antimicrobial susceptibility profile of uncommon NF-GNB isolated from Latin American centers through the SENTRY Program. The in vitro activity of selected antimicrobial agents tested against the unusual NF-GNB isolated from the Latin American region is displayed in Table III . In general, the highest susceptibility rate was obtained with levofloxacin (78.3% susceptible) followed by gatifloxacin (75.6%) > meropenem (72.6%) > imipenem (69.9%) > trimethoprim/ sulfamethoxazole (68.6%), and piperacillin/tazobactam (67.4%). Although the fluoroquinolones had shown an identical in vitro potency (MIC 50 , 1 mg/ml), ciprofloxacin showed the lowest susceptibility rate (61.4%). The aminoglycosides, amikacin and gentamicin, demonstrated poor in vitro activity against NF-GNB inhibiting less than 30% of isolates at the susceptible breakpoints.
The antimicrobial activity of selected antimicrobial agents against the main genus of NF-GNB is shown in Table IV . With the exception of imipenem and meropenem that inhibited 100% of the Alcaligenes spp. isolates, none of the antimicrobial agents tested inhibited 100% of other NF-GNB genus.
Within the Burkholderia genus, B. cepacia complex represents the most important constituent as observed in this study. B. cepacia complex was subdivided by DNA-DNA hybridization, whole-cell protein pattern similarity, and phenotypic markers into five genomic species or genomovars, including B. multivorans (formerly genomovar II), B. stabilis (formerly genomovar IV), and B. vietnamiensis (formerly genomovar V). Genomovar III can be further subdivided into two groups on the basis of recA sequences (groups IIIA and IIIB). More recently, four new members of the B. cepacia complex have been identified: genomovar VI, B. ambifaria (genomovar VII), B. pyrrocinia (genomovar IX), and B. anthina (genomovar VIII) (Detsika et al. 2003) . The distinction of these genomic species is very difficult to achieve using only phenotypic tests. Thus, routine clinical microbiology laboratories will group these genomovars under a unique species named B. cepacia. B. cepacia complex isolates are intrinsically resistant to aminoglycosides and are often multidrug resistant (Beringer et al. 2000) . Among Burkholderia spp. isolates, an important variation on the susceptibility rates of compounds belonging to the same class was noticed. Susceptibility rates varied from 79.5% for meropenem to 60.2% for imipenem, and from 83.1% for ceftazidime to 51.8% for cefepime. In this study, ceftazidime (MIC 50 , 4 µg/ml; 83.1% susceptible) was the most active β-lactam against B. cepacia, in contrast to results reported by previous studies that showed meropenem as the most active β-lactam (Visalli et al. 1997 , Bonacorsi et al. 1999 ). In addition, these studies also reported that trimethoprim/sulfamethoxazole was the most active non-β-lactam drug. In the present study, levofloxacin (MIC 50 , 1 µg/ml; 81.9% susceptible and gatifloxacin (MIC 50 , 1 µg/ ml; 79.5% susceptible) were more active than trimethoprim/sulfamethoxazole (MIC 50 , ≤ 0.5 µg/ml; 71.1% susceptible) against B. cepacia. These fluoroquinolones have shown good activity against Burkholderia spp. in previous studies (Biedenbach et al. 1999 , Dawis et al. 2003 .
Achromobacter xylosoxidans was briefly classified as genus Alcaligenes but was recently reclassified as Achromobacter (Yabuuchi et al. 1998) . A. xylosoxidans infections have been reported in patients with HIV infection, cancer, cystic fibrosis, transplant, as well as in neonates (Hearn & Gander 1991 , Dupon et al.1993 , Dunne & Maisch 1995 , Manfredi et al. 1997 , Hernandez et al. 1998 . Reported case-fatality rates have varied from 3% for primary or catheter-associated bacteremia to 80% for neonatal infection (Duggan et al. 1996) . Achromobacter strains are frequently resistant to aminoglycosides, ampicillin, first-and second-generation cephalosporins, and chloramphenicol, but are usually susceptible to antiPseudomonas third-generation cephalosporins, imipenem, and trimethoprim-sulfamethoxazole (Reverdy et al. 1984 , Klinger & Thomassen 1985 , Mandell et al. 1987 , Bizet et al. 1993 . In the present study, 23 out of 25 Achromobacter isolates were identified as A. xylosoxidans. The car-bapenems were the most active antimicrobial drugs, especially meropenem (MIC 50 , 0.25 µg/ml; 88% susceptible), which was four-fold more potent than imipenem (MIC 50 , 2 µg/ml; 84% susceptible). In contrast, amikacin had poor activity against these isolates. Piperacillin/tazobactam (MIC 50 , 1 µg/ml; 76% susceptible) was also very active against Achromobacter spp. with susceptibility rate higher than that of trimethoprim/sulfamethoxazole (MIC 50 , ≤ 0.5 µg/ ml; 68% susceptible) and levofloxacin (MIC 50 , 2 µg/ml; 68% susceptible). Our results are similar to those published by other investigators (Reverdy et al. 1984 , Klinger & Thomassen 1985 , Mandell et al. 1987 , Bizet et al. 1993 , Saiman et al. 2001 .
The genus Chryseobacterium, defined in 1994 by Vandamme et al., comprises six species, including C. meningosepticum (previously Flavobacterium menin-gosepticum) and C. indologenes (previously F. indologenes), which are the most common clinical species of this genus (Vandamme et al. 1994) .
C. meningosepticum isolates are associated with meningitis in newborns or in immunocompromised patients, while C. indologenes is responsible mostly for nosocomial infections linked to the use of intravascular devices (Hsueh et al. 1996 , Bloch et al. 1997 . Chryseobacterium spp. isolates are intrinsically resistant to most β-lactams, including carbapenems, due to production of chromosomally encoded metallo-β-lactamases (Bellais et al. 2000 , Kirby et al. 2004 ). Among the β-lactams, only piperacillin and expanded-spectrum cephalosporins show in vitro activity against C. indologenes (Fraser & Jorgensen 1997) . Chryseobacterium spp. isolates are also resistant to aminoglycosides, tetracyclines, and chloramphenicol. All Chryseobacterium spp. isolates (12 strains) evaluated were resistant to imipenem and meropenem, and 75% of strains were also resistant to amikacin. Trimethoprim/sulfamethoxazole (MIC 50 , >1µg/ml) was active against only 36.4% of Chryseobacterium spp. strains, and gatifloxacin (MIC 50 , 0.5 µg/ml) and levofloxacin (MIC 50 , 0.5 µg/ml) were the most active compounds (75% susceptible). As shown in a previous study, the fluoroquinolones seem to be the most effective antimicrobials against Chryseobacterium spp. (Kirby et al. 2004) . However, the clinical use of the newer fluoroquinolones must be cautiously evaluated since therapeutic failure has been described with the use of ciprofloxacin (Gungor et al. 2003) . Although vancomycin alone or in combination has been suggested as one of the therapeutic choices against C. meningosepticum infections 
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a: minimal inhibitory concentration was determined by broth microdilution method. b: susceptibility rates calculated according to the criteria published by the NCCLS for testing nonEnterobacteriaceae except for trimethoprim/sulfamethoxazole. Isolates exhibiting MICs ≥ 1 µg/ml were considered as resistant to trimethoprim/sulfamethoxazole; Pip/Taz, piperacillin/ tazobactam; Trim/Sulfa, trimethoprim/sulfamethoxazole; -untested concentration. (Gungor et al. 2003) , in vitro resistance has also been observed in more recent studies (Bloch et al. 1997 , Fraser & Jorgensen 1997 , Kirby et al. 2004 . Ralstonia is a new genus that includes former members of Burkholderia species (B. pickettii and B. sola-nacearum) , Alcaligenes eutrophus and CDC IVc-2 (Beringer et al. 2000) . R. pickettii (formerly Pseudomonas picketti and B. pickettii) is a NF-GNB of relatively low virulence that can cause serious infections in im-munocompromised hosts (Beringer et al. 2000) . Although outbreaks have been reported, it is often associated with pseudobacteremia or asymptomatic colonization of patients. Contamination of water supplies, skin disinfectants, and saline solutions used either for patient care or for laboratory diagnosis have been incriminated (Roberts et al. 1990 , Luk 1996 , Labarca et al. 1999 . Previous studies have shown that usually R. picketti isolates are susceptible to trimethoprim/sulfamethoxazole (Fung-Tomc et al. 1997 ). However, 12.5% of the R. picketti isolated by the Latin American medical centers had trimethoprim/sulfamethoxazole MICs ≥ 1 µg/ ml. The good activity of the ceftriaxone (MIC 50 , 1 µg/ml; 87.5% susceptible), piperacillin/tazobactam (MIC 50 , 8 µg/ml; 87.5% susceptible) and gatifloxacin (MIC 50 , 0.25 µg/ml; 87.5% susceptible) observed in this study are in accordance with earlier studies (Fung-Tomc et al. 1997 .
As more patients are rendered immunossupressed by chemotherapy, transplant or HIV infection, the increasing role of NF-GNB in hospital-acquired infections will be assured. Accurate identification of multiply antimicrobial-resistant gramnegative bacilli is critical to facilitate our understanding of the epidemiology of emerging pathogens. Furthermore, accurate identification and susceptibility testing of NF-GNB have important implications for patient treatment and guidance of infection control standards if patient-to-patient transmission is observed. In this context, surveillance programs such as the SENTRY Program, are very helpful by providing the most common susceptibility profile of these infrequent pathogens and, in this manner, guide the best empirical antimicrobial treatment of such infections. vestigaciones Biológicas, Medellín, Colombia; ; José Sifuentes-Osornio (Instituto Nacional de la Nutrición, Ciudad del México, México); Homero Bagnulo (Hospital Maciel, Montevideo, Uruguay; and Manuel Guzmán-Blanco (Hospital Vargas, Caracas, Venezuela; 1998 -2002 .
